EUVIMEDEUVIMED entdecken
Crossref

Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts

Georgios Kokkotis, Eirini Filidou, Gesthimani Tarapatzi, Michail Spathakis, Leonidas Kandilogiannakis, Nikolas Dovrolis, Konstantinos Arvanitidis, Ioannis Drygiannakis, Vassilis Valatas, Stergios Vradelis, Vangelis G Manolopoulos, Vasilis Paspaliaris und 2 weitere

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izae098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Georgios Kokkotis und 13 weiteren Autor:innen. Beteiligte Einrichtung: GI-Unit, 3rd Department of Internal Medicine, Sotiria Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Oncostatin M, Myofibroblasts, Intestinal Mucosa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Establishment of a Center of Excellence for Pharmacological Studies and Precision Medicine-IMPReS, Competitiveness, Entrepreneurship, and Innovation, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oncostatin-M (OSM) is associated with antitumor necrosis factor (anti-TNF)-α resistance in inflammatory bowel disease (IBD) and fibrosis in inflammatory diseases. We studied the expression of OSM and its receptors (OSMR, gp130) on intestinal subepithelial myofibroblasts (SEMFs) and the effect of OSM stimulation on SEMFs.

Methods

The mRNA and protein expression of OSM, OSMR, gp130, and several fibrotic and chemotactic factors were studied in mucosal biopsies and isolated human intestinal SEMFs of patients with IBD and healthy controls (HCs) and in a model of human intestinal organoids (HIOs). Subepithelial myofibroblasts and HIOs were stimulated with OSM and interleukin (IL)-1α/TNF-α. RNAseq data of mucosal biopsies were also analyzed.

Results

Oncostatin-M receptors and gp130 were overexpressed in mucosal biopsies of patients with IBD (P < .05), especially in inflamed segments (P < .05). The expression of OSM, OSMR, and gp130 in SEMFs from HCs was increased after stimulation with IL-1α/TNF-α (P < .001; P < .01; P < .01). The expression of CCL2, CXCL9, CXCL10, and CXCL11 was increased in SEMFs from patients with IBD and HCs after stimulation with OSM in a dose-dependent manner (P < .001; P < .05; P < .001; P < .001) and was further increased after prestimulation with IL-1α/TNF-α (P < .01 vs OSM-alone). Similar results were yielded after stimulation of HIOs (P < .01). Oncostatin-M did not induce the expression of collagen I, III, and fibronectin. Oncostatin-M receptor expression was positively correlated with CCL2, CXCL9, CXCL10, and CXCL11 expression in mucosal biopsies (P < .001; P < .001; P = .045; P = .033).

Conclusions

Human SEMFs overexpress OSMR in an inflammatory microenvironment. Oncostatin-M may promote inflammation in IBD via its stimulatory effects on SEMFs, which primarily involve chemoattraction of immune cells to the intestinal mucosa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncostatin MMyofibroblastsIntestinal MucosaHumansInflammatory Bowel DiseasesPhenotypeCase-Control StudiesCytokine Receptor gp130Receptors, Oncostatin MOrganoidsFemaleMaleTumor Necrosis Factor-alphaAdultCells, CulturedOncostatin M Receptor beta Subunit

Stichwörter der Autor:innen

chemoattractionfibroblastinflammatory bowel diseaseoncostatin-M

Substanzen

Oncostatin MOSM protein, humanCytokine Receptor gp130Receptors, Oncostatin MTumor Necrosis Factor-alphaOSMR protein, humanOncostatin M Receptor beta Subunit

Autor:innen und Institutionen

  • GI-Unit, 3rd Department of Internal Medicine, Sotiria Hospital, Athens, Greece.
  • Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
  • Individualised Medicine & Pharmacological Research Solutions Center (IMPReS), Alexandroupolis, Greece.
  • Gastroenterology and Hepatology Research Laboratory, Medical School, University of Crete, Heraklion, Greece.
  • Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
  • Tithon Biotech Inc., San Diego, CA, USA.

ORCID-Profile: Giorgos Bamias

Förderung

  • Establishment of a Center of Excellence for Pharmacological Studies and Precision Medicine-IMPReS
  • Competitiveness, Entrepreneurship, and Innovation
  • European Regional Development Fund

Zitieren

APA

Kokkotis, G., Filidou, E., Tarapatzi, G., Spathakis, M., Kandilogiannakis, L., Dovrolis, N., Arvanitidis, K., Drygiannakis, I., Valatas, V., Vradelis, S., Manolopoulos, V. G., Paspaliaris, V., Kolios, G., & Bamias, G. (2024). Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae098

Vancouver

Kokkotis G, Filidou E, Tarapatzi G, Spathakis M, Kandilogiannakis L, Dovrolis N, et al. Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izae098

BibTeX
@article{Kokkotis2024,
  author = {Kokkotis, Georgios and Filidou, Eirini and Tarapatzi, Gesthimani and Spathakis, Michail and Kandilogiannakis, Leonidas and Dovrolis, Nikolas and Arvanitidis, Konstantinos and Drygiannakis, Ioannis and Valatas, Vassilis and Vradelis, Stergios and Manolopoulos, Vangelis G and Paspaliaris, Vasilis and Kolios, George and Bamias, Giorgos},
  title = {Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izae098}
}
Kostenlos starten →